Abstract |
Orally administered metoclopramide ( REGLAN) at doses of 10 or 20 mg, 75 min prior to either stressful linear acceleration (parabolic flight) or cross-coupled accelerative semicircular canal stimulation in a rotating chair was evaluated for its ability to prevent emesis or nausea II, respectively. Although metoclopramide is an effective antiemetic agent that enhances gastric emptying and prevents cancer chemotherapy-induced emesis, we were unable to demonstrate any significant (p less than 0.05) effects of this drug on motion sickness.
|
Authors | R L Kohl |
Journal | Aviation, space, and environmental medicine
(Aviat Space Environ Med)
Vol. 58
Issue 2
Pg. 125-31
(Feb 1987)
ISSN: 0095-6562 [Print] United States |
PMID | 3827787
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Acceleration
(adverse effects)
- Adult
- Coriolis Force
- Humans
- Metoclopramide
(therapeutic use)
- Motion Sickness
(drug therapy, etiology)
- Nausea
(drug therapy, etiology)
- Space Flight
|